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Typical absence seizures characterize numerous idiopathic generalized 
epilepsies and appear in the electroencephalogram (EEG) as bilater-
ally synchronous spike-and-wave discharges (SWDs) accompanied 
by behavioral arrest1,2. Whereas absence seizures are known to arise 
in thalamo–cortical networks2–4, the underlying cellular mechanisms 
are not fully understood. Impaired GABAergic inhibition remains 
an attractive hypothesis5,6, and GABAA receptor (GABAAR) sub-
unit mutations have been identified in human cohorts with typical 
absence seizures, albeit as part of a complex phenotype7–9. However, 
although some of these mutations compromise GABAAR function in 
heterologous expression systems10, only modest changes in GABAAR 
inhibition have so far been identified in the thalamo-cortical net-
work of rodents with spontaneous SWDs11–13. Furthermore, systemic 
or intrathalamic administration of agents that promote GABAergic 
 inhibition, including the antiepileptic drugs vigabatrin and tiagabine, 
initiate or exacerbate seizures in humans and rodents14–18. Thus, 
 augmented rather than impaired GABAAR inhibition may be a feature 
of absence seizures.
Activation of GABAARs generates two types of inhibition: the 
transient activation of synaptic GABAARs (sGABAARs) elicits 
inhibitory postsynaptic currents (IPSCs), or ‘phasic’ inhibition; and 
the activation of peri- or extrasynaptic GABAARs (eGABAARs) by 
ambient GABA causes a persistently active, or tonic, current19,20. 
Because in thalamocortical neurons, major players in thalamo– 
cortical networks during SWDs, >90% of GABAAR inhibition is 
tonic21–24, we have examined the prospect of aberrant tonic inhibition 
in experimental absence seizures. Our data indicate that enhanced 
tonic GABAA inhibition is a common feature of diverse genetic and 
pharmacological models of typical absence epilepsy and may be a 
requirement for the appearance of absence seizures.
RESULTS
Enhanced tonic GABAA current in genetic models of absence
Genetic absence epilepsy rats from Strasbourg (GAERS) are a well 
established polygenic model of absence epilepsy that show bilat-
eral spontaneous SWDs and accompanying behavioral arrest from 
approximately postnatal day 30 (P30)16. In thalamocortical neu-
rons, tonic GABAA currents are generated by extrasynaptic receptors 
containing the δ subunit21–23, and, in rats, δ subunit expression is 
apparent only from approximately P12 (ref. 25). Therefore, we mea-
sured tonic GABAA current amplitude from thalamocortical neu-
rons in slices of the somatosensory ventrobasal thalamus of GAERS 
from P14 onward and compared it to non–epileptic control (NEC) 
rats of the same age. We observed no significant difference in tonic 
current amplitude at P14–P16 (P > 0.05 for each day) (Fig. 1a,b). 
At P17, however, there was an approximately twofold increase in tonic 
current amplitude in GAERS compared to NEC rats (P < 0.05) that 
was sustained in subsequent days (Fig. 1a,b) and was independent of 
whole-cell capacitance (Supplementary Results and Supplementary 
Fig. 1a). Comparison of spontaneous IPSC (sIPSC) parameters 
in GAERS and NEC rats at the same ages revealed no consistent 
differences (Supplementary Table 1), in agreement with previous data 
obtained from younger GAERS12. Notably, there was a significantly 
(P < 0.05) smaller sIPSC peak amplitude, frequency, charge trans-
fer and total current in GAERS at P18, but these changes were not 
maintained at later ages (Supplementary Table 1). These results 
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show that thalamocortical neurons of GAERS have a selective 
enhancement of eGABAAR function before seizure onset.
We then tested whether increased tonic GABAA current also occurs 
in the spontaneous mutant mouse strains stargazer, lethargic and 
tottering, monogenic models of absence epilepsy that have seizures 
as part of a complex phenotype26. In preseizure mutant mice, tonic 
current amplitude measured from thalamocortical neurons in slices 
of ventrobasal thalamus was not significantly different compared to 
control littermates (P > 0.05) (Supplementary Fig. 1b), whereas it 
was significantly larger in stargazer and lethargic mice after seizure 
(P < 0.01 and P < 0.05, respectively) (Fig. 1c). However, in tottering 
mice after seizure, although tonic current amplitude was not signifi-
cantly different to control littermates, it was of similar magnitude 
to stargazer and lethargic mice after seizure (Fig. 1c). Enhanced 
tonic current amplitude was still apparent in stargazer and lethargic 
mice when normalized to whole-cell capacitance (Supplementary 
Results and Supplementary Fig. 1d). Comparison of sIPSC proper-
ties revealed no difference between mutant and control littermates 
either before or after seizure (Supplementary Table 2). Thus, as in 
GAERS, eGABAAR function is selectively enhanced in stargazer and 
lethargic, but not tottering, mice.
SWD-inducing agents enhance the tonic GABAA current
The systemic or intrathalamic administration of γ-hydroxybutyric acid 
(GHB), a weak GABABR agonist, is an established model of typical 
absence seizures27,28, and the systemic administration of the δ subunit–
selective agonist 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) 
has been shown to induce SWDs29. Therefore, we tested whether these 
agents enhance the tonic GABAA current in thalamocortical neurons. 
In the presence of tetrodotoxin (0.5 µM), application of 0.1–10 µM 
THIP increased tonic current amplitude in thalamocortical neurons 
of the ventrobasal thalamus from normal P21–P26 Wistar rats (all 
P < 0.001) (Fig. 1d,e) as described previously for mice21,23. Similarly, 
in the presence of tetrodotoxin, application of 0.3–3 mM GHB, con-
centrations that induce SWDs in vivo27, significantly increased tonic 
current amplitude in vitro (all P < 0.05) (Fig. 1f,g), despite a reduction 
in IPSC frequency (data not shown)30. The action of 3 mM GHB was 
completely blocked by the GABABR antagonist CGP55845 (10 µM) 
and the putative GHB antagonist NCS–382 (1 mM) (Fig. 1g). Indeed, 
application of CGP55845 alone significantly reduced tonic current 
amplitude to 74.0 ± 10.8% of control (P < 0.05) (Fig. 1g), indicating 
that facilitation of eGABAARs by GABABRs contributes approximately 
one quarter of the tonic GABAA current in normal Wistar rats under 
control conditions.
These data, together with those from GAERS and stargazer and 
lethargic mice, show that enhanced eGABAAR activity in thalamo-
cortical neurons characterizes diverse genetic and pharmacological 
models of typical absence seizures.
GAT-1 malfunction underlies aberrant tonic GABAA inhibition
We next examined the mechanism or mechanisms that give rise to 
enhanced tonic GABAA current in GAERS (Fig. 2). Elevated GABA 
levels have been observed in the ventral thalamus of adult GAERS 
compared to NEC rats31 and may arise from reduced GABA uptake32. 
Therefore, we tested the contribution of aberrant GABA uptake to 
enhanced tonic current in P18–P21 GAERS compared to age-matched 
NEC rats using concentrations of GABA transporter blockers selec-
tive for GAT-1 and GAT-3 (ref. 33). In NEC rats, application of the 
Figure 1 Increased tonic GABAA inhibition in 
genetic and pharmacological models of absence 
seizures. (a) Representative current traces from 
thalamocortical neurons of P14 (top) and P17 
(bottom) NEC rats and GAERS, indicating the 
presence of tonic GABAA currents after the focal 
application of 100 µM gabazine (GBZ, white 
bars). Dotted lines indicate the continuation of 
the initial baseline current for each neuron.  
(b) Comparison of the tonic current amplitude  
in NEC rats and GAERS at the indicated ages. 
(c) Comparison of tonic current amplitude  
in stargazer (stg, P19–P21), lethargic (lh,  
P27–P30) and tottering (tg, P26–P28) mice 
after seizure to respective control littermates of 
the same age (Lit.). (d) Representative current 
trace from a normal Wistar rat thalamocortical 
neuron showing the effect of 3 µM THIP on 
baseline current in the presence of 0.5 µM 
tetrodotoxin (TTX). The dotted line indicates 
the initial baseline current. (e) Comparison 
of tonic current amplitude in the indicated 
concentrations of THIP. (f) Representative 
current traces, in the presence of 0.5 µM 
tetrodotoxin, from two Wistar thalamocortical 
neurons showing the effect of 3 mM GHB 
(right) on tonic current amplitude compared to 
control (left). (g) Comparison of the effects of 
varying concentrations of GHB on tonic current 
amplitude and block of GHB-induced increases 
by the GABABR antagonist CGP55845 (10 µM) 
and the putative GHB receptor antagonist  
NCS-382 (1 mM). Values were normalized to the 
average tonic current amplitude under control conditions. Experiments in d–g were performed on P21–P26 Wistar rats. *P < 0.05, **P < 0.01,  
***P < 0.001. For b, c, e and g, the number of recorded neurons is as indicated. Data are presented as means ± s.e.m.
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GAT-1 blocker NO711 (10 µM) significantly increased tonic current 
compared to control conditions (P < 0.01) (Fig. 2a,b), and application 
of the GAT-3 blocker SNAP5114 (20 µM) increased tonic current 
(P < 0.001) to a greater extent than NO711, in agreement with the 
greater abundance of GAT-3 in the thalamus34,35. Concurrent appli-
cation of NO711 and SNAP5114 in NEC rats increased tonic current 
(P < 0.001) to a greater extent than would be expected by simply 
summing the effects of NO711 and SNAP5114 alone, suggesting that 
blocking of GAT-1 causes a compensatory increase in uptake by GAT-3, 
and vice versa. In GAERS, application of NO711 had no effect on 
tonic current (P > 0.05) (Fig. 2a,b), but application of SNAP5114 
caused a large increase (P < 0.001). Application of NO711 together 
with SNAP5114 in GAERS significantly increased tonic current 
(P < 0.001), but the increase was similar to that observed after appli-
cation of SNAP5114 alone and after application of NO711 and 
SNAP5114 together in NEC rats (Fig. 2a,b). Compromised GABA 
uptake by GAT-1 is therefore responsible for enhanced tonic current, 
as blocking GAT-1 in GAERS had no effect on tonic current ampli-
tude, blocking GAT-1 in NEC rats increased tonic current amplitude 
to similar values to those seen in GAERS under control conditions, 
and the compensatory increase in uptake by GAT-1 after blocking 
GAT-3 is lost in GAERS.
We also tested whether increased vesicular GABA release, over-
expression of eGABAARs, mis-expression of sGABAARs or aber-
rant taurine transport contribute to enhanced tonic current in 
GAERS, but none of these cellular mechanisms were implicated 
(Supplementary Results and Supplementary Fig. 2). However, 
because our data in normal Wistar rats showed that activation of 
GABABRs contributes to tonic GABAA current (Fig. 1g), we tested 
whether modulation of eGABAARs by GABABRs occurs in GAERS. 
In P18–P21 GAERS, CGP55845 (10 µM) significantly reduced tonic 
current amplitude to 54.7 ± 9.5% of control (P < 0.05) (Fig. 2e), 
indicating that facilitation of eGABAAR function by GABABR 
activation contributes almost half of the tonic current in GAERS.
To determine whether compromised GAT-1 activity is restricted to 
neurons that participate in seizure genesis, we tested the effects of NO711 
on tonic GABAA current in dentate gyrus granule cells (DGGCs) of GAERS, 
as the hippocampal formation is not involved in the generation or main-
tenance of SWDs16. Under control conditions, no tonic current was observed 
in DGGCs of either P18–P21 GAERS or NEC rats (data not shown), 
and sIPSCs were similar in the two strains (Supplementary Table 3). 
Application of 10 µM NO711, however, induced a tonic current of similar 
amplitude in both GAERS and NEC rats (Supplementary Fig. 3), indicat-
ing that GAT-1 activity is normal in the dentate gyrus of GAERS.
We also tested whether compromised GAT-1 activity underlies 
enhanced eGABAAR function in stargazer and lethargic mice. In 
stargazer mice, similar to GAERS, there was no effect of GAT-1 block 
by NO711 on tonic current amplitude, and block of GAT-3 alone by 
SNAP5114 caused a similar increase to that achieved by application 
of NO711 and SNAP5114 together (P < 0.01 and 0.001, respectively) 
(Fig. 2c). In stargazer littermates, NO711 increased tonic current 
(P < 0.05) to the same level as in stargazer mice under control condi-
tions (Fig. 2c). In contrast, in lethargic mice, NO711 significantly 
decreased tonic current amplitude compared to control conditions 
(P < 0.01), and in lethargic littermates NO711 increased tonic cur-
rent (P < 0.001) to similar values to those seen in lethargic mice 
under control conditions (Fig. 2d). Thus, in stargazer mice, as in 
GAERS, increased eGABAAR activity is caused by a failure of GABA 
uptake by GAT-1. However, in lethargic mice, GAT-1 seems to be a 
source of ambient GABA, implying that GABA transport by GAT-1 
is reversed36. To test whether GABABR activation contributes to 
enhanced tonic inhibition in stargazer and lethargic mice, we mea-
sured tonic current amplitude in the presence of CGP55845 (10 µM). 
Similarly to the results in GAERS, application of CGP55845 reduced 
Figure 2 Aberrant GABA uptake by GAT-1 
underlies enhanced tonic inhibition in GAERS, 
stargazer and lethargic. (a) Representative 
current traces in P18–P21 NEC rats and 
GAERS showing the effects of block of  
GAT-1 alone (after bath application of  
10 µM NO711, top traces), GAT-3 alone 
(20 µM SNAP5114, middle traces) and 
GAT-1 and GAT-3 together (NO. + SNAP., 
bottom traces), on tonic current amplitude, 
revealed by focal application of 100 µM GBZ 
(white bars). (b) Comparison of the effects 
of application of NO711 and SNAP5114 
alone, and their application together, on tonic 
current amplitude in NEC rats and GAERS. 
(c) Comparison of the effect of NO711 and 
SNAP5114 alone, and their concurrent 
application, on tonic current amplitude 
in P19–P21 stargazer mice and control 
littermates. (d) Comparison of the effect  
of NO711 on tonic current amplitude in  
P27–P30 lethargic mice and control 
littermates. (e) Comparison of the effect of 
bath application of 10 µM CGP55845 on  
tonic current amplitude in GAERS and 
stargazer and lethargic mice. Values were 
normalized to the average tonic current 
amplitude in the absence of CGP55845.  
In b–d, *P < 0.05, **P < 0.01 and  
***P < 0.001 for mutant versus non–mutant 
rats or mice under control conditions; †P < 0.05, $P < 0.01 and #P < 0.001for drug versus non–drug for each strain. In e, *P < 0.05 for control 
versus CGP55845. For b–e, the number of recorded neurons is as indicated. Data are presented as means ± s.e.m.
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tonic current amplitude to 64.4 ± 15.7% in stargazer mice and 
52.7 ± 7.9% in lethargic mice (P < 0.05 for both) (Fig. 2e).
In summary, these data show that increased tonic GABAA current 
in thalamocortical neurons of GAERS and stargazer and lethargic 
mice is caused by loss of GABA uptake by GAT-1. However, GAT-1 
function in DGGCs is unaltered, and GAT-1 expression levels are 
normal in thalamus and cortex of GAERS (Supplementary Results 
and Supplementary Fig. 4). We suggest that the resultant increase 
in ambient GABA in the thalamus leads to enhanced tonic current 
through direct activation of eGABAARs and a GABABR-dependent 
facilitation of eGABAAR function.
Thalamic GAT-1 controls absence seizures
In light of the fact that compromised GAT-1 activity causes enhanced 
tonic inhibition in thalamocortical neurons of GAERS and stargazer 
and lethargic mice, we predicted that GAT-1–knockout mice should 
show both enhanced tonic inhibition and spontaneous SWDs. Tonic 
current is indeed increased in cerebellar and cortical neurons of GAT-1– 
knockout mice37,38, but thalamocortical neurons have not been tested. 
Similarly, GAT-1–knockout mice have increased susceptibility to 
pentylenetetrazole-induced seizures37, but the presence of spontan-
eous SWDs has not been determined. In thalamocortical neurons of 
P68–P74 GAT-1–knockout mice, tonic current amplitude was signifi-
cantly larger compared to age-matched wild-type (WT) littermates 
(P < 0.01) (Fig. 3a,b), and normalized tonic current amplitude was also 
larger (P < 0.01) (data not shown). Furthermore, sIPSC properties were 
also significantly different (P < 0.05) (Supplementary Table 3). Freely 
moving GAT-1–knockout mice showed spontaneous absence seizures, 
with SWDs having a mean frequency of 5.2 ± 0.1 Hz (range 4.7–5.7 Hz, 
n = 10 SWDs in each of eight mice) (Fig. 3c) that were blocked by 
systemic administration of the antiabsence drug ethosuximide 
(200 mg per kg body weight intaperitoneally (i.p.), P < 0.001) (Fig. 3d). 
Notably, ethosuximide (750 µM) and another antiabsence drug, 
sodium valproate (500 µM), had no effect on tonic current ampli-
tude (Supplementary Fig. 5). Thus, as predicted, GAT-1–knockout 
mice have both enhanced tonic inhibition in thalamocortical neurons 
and spontaneous SWDs.
We further tested the role of thalamic GAT-1 in the generation of SWDs 
by intrathalamic reverse microdialysis of the selective GAT-1 inhibitor 
NO711 (200 µM, effective concentration ≤20 µM, see Online Methods 
for details) in normal Wistar rats. Application of NO711 induced both 
behavioral and electrographic correlates of seizures in all rats tested 
(Fig. 3e,f and Supplementary Movie 1), and SWDs had a mean fre-
quency of 8.7 ± 1.3 Hz (range 5.0–15.3 Hz, n = 10 SWDs from each of 
five rats). Systemic application of ethosuximide (100 mg per kg body 
weight i.p.) significantly reduced both the time spent in seizure and the 
number of SWDs after NO711 administration in all rats tested (Fig. 3g,h) 
(P < 0.05). Thus, intrathalamic NO711 administration is sufficient for the 
appearance of absence seizures, and these two sets of experiments show 
that thalamic GAT-1 is crucial in controlling the generation of SWDs.
eGABAARs are a requirement for seizure generation
To assess the importance of enhanced eGABAAR function to 
seizure generation in two well established models of absence epilepsy, 
GHB treatment and GAERS, we performed two sets of experiments. 
First, we determined whether mice without thalamic eGABAARs 
were resistant to the pharmacological induction of absence seizures. 
GABAAR δ subunit knockout (δ-knockout) mice had reduced tonic 
inhibition in thalamocortical neurons (P < 0.01) (Fig. 4a–c)39, 
whereas sIPSCs were largely unaffected (Supplementary Table 3). 
In WT littermates, systemic administration of the GHB pro-drug 
γ-butyrolactone (50 mg per kg body weight i.p.)40 readily induced 
absence seizures (Fig. 4d,e) that were largely abolished after 
 administration of ethosuximide (200 mg per kg body weight i.p., 
Figure 3 Role of thalamic GAT-1 in the 
generation of SWDs. (a) Representative current 
traces from P68–P74 WT and GAT-1–knockout 
(GAT–1 KO) mice indicating the presence of 
tonic currents after the focal application of  
100 µM GBZ (white bars). (b) Comparison  
of tonic current amplitude in WT and  
GAT–1–knockout (KO) mice. Numbers  
of recorded neurons are as indicated.  
(c) Simultaneous, bilateral (L, left hemisphere; 
R, right hemisphere) EEG traces from a 
GAT–1–knockout mouse showing spontaneous 
SWDs under control conditions. At the bottom 
is a spectrogram corresponding to the R trace. 
AU, arbitrary units. (d) Comparison of the 
effect of ethosuximide (ETX) (200 mg per kg 
body weight i.p.) on the total time (over 1 h) 
spent in seizure. Number of recorded mice 
is as indicated. (e) Simultaneous, bilateral 
EEG traces from a normal Wistar rat after 
intrathalamic administration of artificial 
cerebrospinal fluid (aCSF, top traces) and then 
200 µM NO711 (bottom traces). Second from 
bottom is a spectrogram for the lowest trace L. 
At the bottom is an enlargement of the single 
SWD indicated (•). Calibration bars for the 
enlarged SWD; vertical 200 µV, horizontal 1 s. 
(f) Graph showing the effects of intrathalamic 
administration of NO711 on the time  
(20-min periods) spent in seizure, compared to aCSF administration. (g,h) Comparison of the effects of systemic ETX (100 mg per kg body weight i.p.) 
administration on total time (over 2 h) spent in seizure (g), and total number of SWDs (h), during intrathalamic NO711 administration. *P < 0.05,  
**P < 0.01 and ***P < 0.001. Data are presented as means ± s.e.m.
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P < 0.001) (Fig. 4f). However, γ-butyrolactone administration only 
rarely induced SWDs in δ-knockout mice (Fig. 4d–f).
In the second set of experiments, we intrathalamically injected 
δ subunit–specific antisense oligodeoxynucleotides in GAERS to 
knock down δ subunit expression and therefore decrease the number 
of eGABAARs
41. In rats treated with antisense oligodeoxynucleotides 
(1 or 2 nmol per site), the time spent in seizure and the number of 
SWDs were significantly reduced (P < 0.05) 1–2 d after injection 
(Fig. 5a,b) compared to control. By comparison, injection of a mis-
sense oligodeoxynucleotide (1–2 nmol per site) had no effect on 
spontaneous seizures (Fig. 5a,b). Notably, injection of the missense 
oligodeoxynucleotide (2 nmol per site) also had no effect on tonic 
inhibition in P28–P32 GAERS, compared to age-matched, untreated 
rats, whereas the antisense oligodeoxynucleotide (2 nmol per site) 
significantly reduced tonic current amplitude (P < 0.05) (Fig. 5c). 
Also, neither missense or antisense oligodeoxynucleotides had any 
effect on sIPSCs (Supplementary Table 3). Oligodeoxynucleotide 
spread was restricted to the thalamus after post hoc visualization of 
a unilaterally injected biotinylated antisense oligodeoxynucleotide 
(Fig. 5d). The results from these two sets of experiments demon-
strate that enhanced eGABAAR function in the thalamus is crucial for 
the appearance of absence seizures in two of the best characterized 
 models of absence epilepsy.
Enhanced eGABAAR function is sufficient for absence seizures
To directly test whether enhanced eGABAAR function in thalamocor-
tical neurons is sufficient for absence seizures, we used intrathalamic 
administration of the eGABAAR agonist THIP (30–100 µM, effective 
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concentration ≤3–10 µM, see Online Methods for details) by reverse 
microdialysis in normal Wistar rats to determine whether selectively 
increasing tonic inhibition initiates absence seizures in rats that do not 
normally have them. THIP induced SWDs in only one out of six rats 
at low concentrations (30 µM, data not shown) but robustly induced 
the electrographic and behavioral correlates of absence seizures at 
concentrations of 70 and 100 µM (Fig. 6a,b and Supplementary 
Movie 2). THIP-induced SWDs had a frequency of 6.1 ± 0.9 Hz 
(range 5.2–7.5 Hz, n = 10 SWDs in each of four rats), increased in 
duration during the recording period (Fig. 6a), and were blocked 
by ethosuximide administration (100 mg per kg body weight i.p., 
P < 0.05) (Fig. 6c,d). Because THIP at the concentrations used is 
selective for δ subunit–containing eGABAARs42, our data show that 
enhanced eGABAAR function in thalamocortical neurons is sufficient 
for the appearance of absence seizures.
DISCUSSION
Here we have shown that enhanced eGABAAR function is a com-
mon pathophysiological mechanism in all the diverse genetic and 
pharmacological models of absence epilepsy tested, except tottering 
mice (Supplementary Discussion). However, in agreement with 
previous studies, we rarely observed changes in phasic inhibition 
(Supplementary Discussion). Our data also indicate that enhanced 
tonic inhibition is sufficient for seizure genesis and is a requirement 
for the appearance of seizures in some models. Previous studies have 
implicated eGABAARs and GAT-1 in the generation of convulsive 
seizures (Supplementary Discussion), but our data directly demon-
strate a role for both in absence seizures. Moreover, GAT-1–knockout 
mice and intrathalamic NO711 may represent new models of 
absence epilepsy. Compromised GAT-1 activity underlies increased 
tonic inhibition in GAERS and stargazer and lethargic mice, but how 
the genetic variants in these models lead to GAT-1 malfunction is 
unknown. GAT-1 is a target for intracellular modulation, at least in 
neurons43–46, but in the thalamus GABA uptake is governed exclu-
sively by astrocytes34. Thus, thalamic cellular pathology in absence 
seizures may be astrocyte specific.
The potential contribution of eGABAARs to absence seizure genera-
tion is considered in the Supplementary Discussion. Unexpectedly, 
in GAERS, stargazer, lethargic and GHB models, a previously 
unknown GABABR-dependent facilitation of eGABAAR function 
seems to contribute to tonic GABAA inhibition. Although the mech-
anism underlying this facilitation is unknown, our findings help to 
explain the sensitivity of seizures to GABABR modulation, a defining 
criterion for models of absence epilepsy, but do not detract from 
classical pre- and post-synaptic GABABR contributions to seizure 
genesis (Supplementary Discussion).
In conclusion, our data show that enhanced eGABAAR function 
occurs in diverse models of absence seizures and seems to be key in 
seizure genesis. Furthermore, thalamic GAT-1 crucially controls the 
appearance of absence seizures. We, therefore, suggest that thalamic 
eGABAARs and GABA transporters may be potential targets for the 
generation of novel therapies against absence seizures.
METhODS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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ONLINE METhODS
Electrophysiological recordings. We prepared horizontal slices containing 
the ventrobasal thalamus and dentate gyrus in accordance with the United 
Kingdom Animals (Scientific Procedures) Act 1986 and associated procedures, 
as described previously22. We made whole-cell patch clamp recordings from 
visualized ventrobasal thalamocortical neurons and DGGCs held at 33 ± 1 °C, 
and pipettes were attached to the head stage of either a Multiclamp 700B 
preamplifier, controlled by Multiclamp Commander software, or an Axopatch 
200A preamplifier (Molecular Devices). We measured whole-cell capacitance 
in response to small (5-mV) voltage pulses. Experimental data were digitized at 
20 kHz (Digidata 1322, Molecular Devices), acquired using pClamp 9.0 software 
(Molecular Devices) and stored on a personal computer. We performed experi-
ments on only a single neuron within a slice, after which we discarded the slice. 
We bath-applied drugs in the recording medium, except for focal applications 
of GBZ.
We analyzed data using LabView–based software (National Instruments). 
Tonic currents were observed as an outward shift in baseline current after appli-
cation of 100 µM GBZ, and we measured tonic and phasic currents as previously 
described22.
Electroencephalogram recordings in behaving rats and mice. We performed all 
surgical procedures in accordance with the UK Animals (Scientific Procedures) 
Act 1986 and associated procedures. We anesthetized male and female rats and 
mice of the relevant strains with a mixture of isoflurane and N2O, and implanted 
rats with six screw electrodes placed bilaterally over the frontal cortex, parietal 
cortex and cerebellum, and mice with four screws bilaterally over the parietal 
cortex and cerebellum. For injection of antisense and missense oligodeoxynucleo-
tides and reverse microdialysis experiments, we implanted two guide cannulae 
over the ventrobasal thalamus of rats (anterior-posterior –3.1, lateral 3.0, ventral 
4.0; ref. 47) and permanently fixed them to the skull with methylacrylic cement. 
We checked the position of cannulae post hoc (for example, Fig. 5d), and we 
did not include data from rats with incorrectly positioned cannulae for 
further analysis. Antisense and missense oligodeoxynucleotides were injected 
1 week after recovery from implantation, and we determined the spread of 
injected oligodeoxynucleotides with a unilaterally injected biotinylated antisense 
oligodeoxynucleotide visualized by the avidin-biotin–horseradish peroxidase 
 complex procedure (Supplementary Methods). Labeling in the injected hemisphere 
occurred not only in the ventrobasal thalamus but also in the nucleus reticularis 
thalami, caudate putamen, central amygdala and some regions of neocortex. 
However, binding in the caudate putamen, amygdala and neocortex was 
mirrored in the non–injected hemisphere and is therefore non–specific (Fig. 5d). 
For tonic current measurements after oligodeoxynucleotide injection, we killed 
injected rats 22–26 h after injection and prepared slices as described above. 
We performed reverse microdialysis experiments after the bilateral insertion 
of microdialysis probes (CMA/12, 2-mm length and 500-µm outer diameter; 
Carnegie Medicin), connected to a two-channel liquid swivel (Carnegie 
Medicin), to a depth 2 mm below the end of the cannulae.
We made EEG recordings using a Neurolog (Digitimer Ltd) or Plexon (model 
REC/64) amplifier, and analyzed data using pClamp 9.0 (Molecular Devices) 
or Plexon software, respectively. We recorded spontaneous or γ-butyrolactone– 
induced seizures in mice for a period of 1 h. Control recordings were made 
before the injection of oligodeoxynucleotides, and experiments started 1 d 
after injection. For reverse microdialysis experiments, we made EEG record-
ings first without probes (30 min), second with probes infusing aCSF (20 min, 
see Supplementary Methods for composition) and third with probes infusing 
the relevant drug dissolved in aCSF (120 min). Although high concentrations of 
each drug were used, reverse microdialysis reduces the effective concentration of 
administered drug to ≤10% (ref. 48), therefore the final concentrations were selec-
tive for their desired targets. During the recording session, we video-monitored 
rats and mice to record the behavioral components of absence seizures. We 
quantified data as the time spent in seizure during 15-min periods for mice and 
20-min periods for rats, and we also calculated the total number of SWDs in 
some instances. The effect of ethosuximide on spontaneous and drug-induced 
seizures was tested by i.p. injection at doses of 100–200 mg per kg body weight 
in a volume of 1 ml kg–1.
Statistical analyses. For comparison of tonic current amplitude and IPSC prop-
erties between mutant and control rats and mice and between neurons recorded 
under control conditions and in the presence of drugs, we used Student’s unpaired 
t test with significance set at P < 0.05. For EEG recordings, we assessed drug 
effects by repeated-measures ANOVA with post hoc Tukey’s honestly significant 
test when we found significant differences (P < 0.05). We compared the effects 
of ethosuximide on seizures with Student’s paired t test (P < 0.05). All data are 
presented as means ± s.e.m.
Additional methods. Detailed methodology is described in the Supplementary 
Methods.
47. Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates 2nd edn. (Academic 
Press, San Diego, 1986).
48. Juhász, G., Kékesi, K., Emri, Z., Soltesz, I. & Crunelli, V. Sleep-promoting action 
of excitatory amino acid antagonists: a different role for thalamic NMDA and 
non-NMDA receptors. Neurosci. Lett. 114, 333–338 (1990).©
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